Details of the Drug

General Information of Drug (ID: DMRMS0L)

• Drug Name: Morphine
• Synonyms: Avinza; Kadian; Morphine Sulfate; Depodur; Astramorph Pf; Duramorph Pf; Infumorph; Ms Contin; Oramorph Sr

Indication

Disease Entry	ICD 11	Status	REF
Advanced cancer	2A00-2F9Z	Approved	[1]
Chronic pain	MG30	Approved	[2]
Pain	MG30-MG3Z	Approved	[1]
Diarrhea	ME05.1	Investigative	[1]

• Therapeutic Class: Analgesics
• Affected Organisms: Humans and other mammals
• ATC Code:
  N02AA01: Morphine
  N02AA: Natural opium alkaloids
  N02A: OPIOIDS
  N02: ANALGESICS
  N: NERVOUS SYSTEM
  N02AA01: Morphine
  N02AA: Natural opium alkaloids
  N02A: OPIOIDS
  N02: ANALGESICS
  N: NERVOUS SYSTEM
  N02AA01: Morphine
  N02AA: Natural opium alkaloids
  N02A: OPIOIDS
  N02: ANALGESICS
  N: NERVOUS SYSTEM
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 285.34
  Logarithm of the Partition Coefficient (xlogp); 0.8
  Rotatable Bond Count (rotbonds); 0
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 4
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
  Bioavailability: The bioavailability of drug is 78% [4]
  Clearance: The clearance of drug is 1600 mL/min [5]
  Elimination: 70-80% of an administered dose is excreted within 48 hours [6]
  Half-life: The concentration or amount of drug in body reduced by one-half in 2 - 3 hours [7]
  Metabolism: The drug is metabolized via the glucuronidation by UGT2B7 and sulfation at positions 3 and 6 [8]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 5.85255 micromolar/kg/day [9]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.65% [10]
  Vd: The volume of distribution (Vd) of drug is 5.31 L/kg [6]
  Water Solubility: The ability of drug to dissolve in water is measured as 57.14 mg/mL [3]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Hyperpathia	Not Available	PRKCA PKCA PRKACA	OT5UWNRD	[11]
Hyperpathia	Not Available	JUN	OTCYBO6X	[11]
Hyperpathia	Not Available	MAPK8	OTEREYS5	[11]

• Chemical Identifiers:
  Formula: C17H19NO3
  IUPAC Name: (4R,4aR,7S,7aR,12bS)-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol
  Canonical SMILES: CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O
  InChI: InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2-5,10-11,13,16,19-20H,6-8H2,1H3/t10-,11+,13-,16-,17-/m0/s1
  InChIKey: BQJCRHHNABKAKU-KBQPJGBKSA-N
• Cross-matching ID:
  PubChem CID: 5288826
  ChEBI ID: CHEBI:17303
  CAS Number: 57-27-2
  UNII: 76I7G6D29C
  DrugBank ID: DB00295
  TTD ID: D0WE3O
  VARIDT ID: DR00467
  INTEDE ID: DR1112
  ACDINA ID: D00447
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Opioid receptor mu (MOP)	TTKWM86	OPRM_HUMAN	Modulator	[12]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Multidrug resistance-associated protein 3 (ABCC3)	DTQ3ZHF	MRP3_HUMAN	Substrate	[13]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[14]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[15]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[16]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Substrate	[17]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[18]
UDP-glucuronosyltransferase 2B7 (UGT2B7) Main DME	DEB3CV1	UD2B7_HUMAN	Substrate	[19]
UDP-glucuronosyltransferase 1A3 (UGT1A3)	DEF2WXN	UD13_HUMAN	Substrate	[20]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Acetylcholinesterase (ACHE)	OT2H8HG6	ACES_HUMAN	Biotransformations	[21]
Apolipoprotein B-100 (APOB)	OTH0UOCZ	APOB_HUMAN	Gene/Protein Processing	[22]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Gene/Protein Processing	[23]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Gene/Protein Processing	[23]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Drug Response	[24]
Bcl-2 homologous antagonist/killer (BAK1)	OTDP6ILW	BAK_HUMAN	Gene/Protein Processing	[25]
Bcl-2-binding component 3, isoforms 3/4 (BBC3)	OTUAXDAY	BBC3B_HUMAN	Gene/Protein Processing	[26]
Bcl-2-like protein 11 (BCL2L11)	OTNQQWFJ	B2L11_HUMAN	Gene/Protein Processing	[27]
Beclin-1 (BECN1)	OT4X293M	BECN1_HUMAN	Gene/Protein Processing	[28]
Beta-arrestin-2 (ARRB2)	OTAEJZCI	ARRB2_HUMAN	Drug Response	[29]

Molecular Expression Atlas of This Drug

• The Studied Disease: Advanced cancer
• ICD Disease Classification: 2A00-2F9Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Opioid receptor mu (MOP)	DTT	OPRM1	5.94E-01	-0.02	-0.17
P-glycoprotein 1 (ABCB1)	DTP	P-GP	7.83E-01	4.69E-02	1.89E-01
Multidrug resistance-associated protein 3 (ABCC3)	DTP	MRP3	8.71E-01	1.90E-02	1.26E-01
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DME	UGT1A1	1.87E-01	4.98E-02	3.61E-01
Cytochrome P450 2C8 (CYP2C8)	DME	CYP2C8	3.17E-01	-6.95E-02	-2.88E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	5.64E-01	2.36E-02	1.75E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	6.06E-01	-2.42E-02	-1.64E-01

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Morphine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Morphine and Dihydrocodeine.	Chronic pain [MG30]	[30]
Levomilnacipran	DMV26S8	Moderate	Additive serotonergic effects by the combination of Morphine and Levomilnacipran.	Chronic pain [MG30]	[31]

Coadministration of a Drug Treating the Disease Different from Morphine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Arn-509	DMT81LZ	Moderate	Increased metabolism of Morphine caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[32]
Gilteritinib	DMTI0ZO	Moderate	Decreased clearance of Morphine due to the transporter inhibition by Gilteritinib.	Acute myeloid leukaemia [2A60]	[33]
Oliceridine	DM6MDCF	Major	Additive CNS depression effects by the combination of Morphine and Oliceridine.	Acute pain [MG31]	[34]
Chlorzoxazone	DMCYVDT	Major	Additive CNS depression effects by the combination of Morphine and Chlorzoxazone.	Acute pain [MG31]	[34]
Scopolamine	DMOM8AL	Moderate	Additive CNS depression effects by the combination of Morphine and Scopolamine.	Addictive disorder [6C50-6C5Z]	[35]
Buspirone	DMBS632	Major	Additive CNS depression effects by the combination of Morphine and Buspirone.	Anxiety disorder [6B00-6B0Z]	[34]
Clorazepate	DMC3JST	Major	Additive CNS depression effects by the combination of Morphine and Clorazepate.	Anxiety disorder [6B00-6B0Z]	[30]
Alprazolam	DMC7XDN	Major	Additive CNS depression effects by the combination of Morphine and Alprazolam.	Anxiety disorder [6B00-6B0Z]	[34]
Methylphenobarbital	DMDSWAG	Major	Additive CNS depression effects by the combination of Morphine and Methylphenobarbital.	Anxiety disorder [6B00-6B0Z]	[30]
Hydroxyzine	DMF8Y74	Major	Additive CNS depression effects by the combination of Morphine and Hydroxyzine.	Anxiety disorder [6B00-6B0Z]	[34]
Halazepam	DMPFWO6	Major	Additive CNS depression effects by the combination of Morphine and Halazepam.	Anxiety disorder [6B00-6B0Z]	[34]
Chlordiazepoxide	DMTN5XI	Major	Additive CNS depression effects by the combination of Morphine and Chlordiazepoxide.	Anxiety disorder [6B00-6B0Z]	[34]
Chlormezanone	DMTWUXR	Major	Additive CNS depression effects by the combination of Morphine and Chlormezanone.	Anxiety disorder [6B00-6B0Z]	[34]
Clobazam - Lundbeck	DMW1OQ0	Major	Additive CNS depression effects by the combination of Morphine and Clobazam - Lundbeck.	Anxiety disorder [6B00-6B0Z]	[34]
Oxazepam	DMXNZM4	Major	Additive CNS depression effects by the combination of Morphine and Oxazepam.	Anxiety disorder [6B00-6B0Z]	[34]
Promazine	DMZAL7W	Major	Additive CNS depression effects by the combination of Morphine and Promazine.	Appearance/behaviour symptom [MB23]	[34]
Desipramine	DMT2FDC	Moderate	Additive CNS depression effects by the combination of Morphine and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[31]
Linezolid	DMGFPU2	Moderate	Additive CNS depression effects by the combination of Morphine and Linezolid.	Bacterial infection [1A00-1C4Z]	[36]
Cariprazine	DMJYDVK	Major	Additive CNS depression effects by the combination of Morphine and Cariprazine.	Bipolar disorder [6A60]	[34]
Loperamide	DMOJZQ9	Moderate	Additive CNS depression effects by the combination of Morphine and Loperamide.	Bowel habit change [ME05]	[32]
Secobarbital	DM14RF5	Major	Additive CNS depression effects by the combination of Morphine and Secobarbital.	Chronic insomnia [7A00]	[34]
PF-04449913	DMSB068	Moderate	Decreased clearance of Morphine due to the transporter inhibition by PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[32]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Morphine and Olopatadine.	Conjunctiva disorder [9A60]	[37]
Propofol	DMB4OLE	Moderate	Additive CNS depression effects by the combination of Morphine and Propofol.	Corneal disease [9A76-9A78]	[38]
Methadone	DMTW6IU	Major	Additive CNS depression effects by the combination of Morphine and Methadone.	Cough [MD12]	[34]
Dextromethorphan	DMUDJZM	Moderate	Additive CNS depression effects by the combination of Morphine and Dextromethorphan.	Cough [MD12]	[31]
Ethanol	DMDRQZU	Major	Additive CNS depression effects by the combination of Morphine and Ethanol.	Cystitis [GC00]	[39]
Sertraline	DM0FB1J	Moderate	Additive serotonergic effects by the combination of Morphine and Sertraline.	Depression [6A70-6A7Z]	[31]
Trimipramine	DM1SC8M	Moderate	Additive serotonergic effects by the combination of Morphine and Trimipramine.	Depression [6A70-6A7Z]	[31]
Cyclobenzaprine	DM1YBRM	Major	Additive CNS depression effects by the combination of Morphine and Cyclobenzaprine.	Depression [6A70-6A7Z]	[34]
Imipramine	DM2NUH3	Moderate	Additive serotonergic effects by the combination of Morphine and Imipramine.	Depression [6A70-6A7Z]	[31]
Fluoxetine	DM3PD2C	Moderate	Additive CNS depression effects by the combination of Morphine and Fluoxetine.	Depression [6A70-6A7Z]	[31]
Nortriptyline	DM4KDYJ	Moderate	Additive serotonergic effects by the combination of Morphine and Nortriptyline.	Depression [6A70-6A7Z]	[31]
Vilazodone	DM4LECQ	Moderate	Additive serotonergic effects by the combination of Morphine and Vilazodone.	Depression [6A70-6A7Z]	[31]
Nefazodone	DM4ZS8M	Moderate	Additive serotonergic effects by the combination of Morphine and Nefazodone.	Depression [6A70-6A7Z]	[31]
Paroxetine	DM5PVQE	Moderate	Additive serotonergic effects by the combination of Morphine and Paroxetine.	Depression [6A70-6A7Z]	[31]
Selegiline	DM6034S	Moderate	Additive CNS depression effects by the combination of Morphine and Selegiline.	Depression [6A70-6A7Z]	[36]
Vortioxetine	DM6F1PU	Moderate	Additive serotonergic effects by the combination of Morphine and Vortioxetine.	Depression [6A70-6A7Z]	[31]
Duloxetine	DM9BI7M	Moderate	Additive CNS depression effects by the combination of Morphine and Duloxetine.	Depression [6A70-6A7Z]	[31]
Isocarboxazid	DMAF1NB	Moderate	Additive CNS depression effects by the combination of Morphine and Isocarboxazid.	Depression [6A70-6A7Z]	[36]
Milnacipran	DMBFE74	Moderate	Additive serotonergic effects by the combination of Morphine and Milnacipran.	Depression [6A70-6A7Z]	[31]
Escitalopram	DMFK9HG	Moderate	Additive CNS depression effects by the combination of Morphine and Escitalopram.	Depression [6A70-6A7Z]	[31]
Tranylcypromine	DMGB5RE	Moderate	Additive CNS depression effects by the combination of Morphine and Tranylcypromine.	Depression [6A70-6A7Z]	[36]
Desvenlafaxine	DMHD4PE	Moderate	Additive CNS depression effects by the combination of Morphine and Desvenlafaxine.	Depression [6A70-6A7Z]	[31]
OPC-34712	DMHG57U	Major	Additive CNS depression effects by the combination of Morphine and OPC-34712.	Depression [6A70-6A7Z]	[34]
Phenelzine	DMHIDUE	Moderate	Additive CNS depression effects by the combination of Morphine and Phenelzine.	Depression [6A70-6A7Z]	[36]
Clomipramine	DMINRKW	Moderate	Additive CNS depression effects by the combination of Morphine and Clomipramine.	Depression [6A70-6A7Z]	[31]
Trazodone	DMK1GBJ	Moderate	Additive serotonergic effects by the combination of Morphine and Trazodone.	Depression [6A70-6A7Z]	[31]
Amitriptyline	DMK7F9S	Moderate	Additive CNS depression effects by the combination of Morphine and Amitriptyline.	Depression [6A70-6A7Z]	[31]
Amoxapine	DMKITQE	Moderate	Additive CNS depression effects by the combination of Morphine and Amoxapine.	Depression [6A70-6A7Z]	[31]
Mirtazapine	DML53ZJ	Moderate	Additive serotonergic effects by the combination of Morphine and Mirtazapine.	Depression [6A70-6A7Z]	[31]
Protriptyline	DMNHTZI	Moderate	Additive serotonergic effects by the combination of Morphine and Protriptyline.	Depression [6A70-6A7Z]	[31]
Doxepin	DMPI98T	Moderate	Additive CNS depression effects by the combination of Morphine and Doxepin.	Depression [6A70-6A7Z]	[31]
Maprotiline	DMPWB7T	Moderate	Additive serotonergic effects by the combination of Morphine and Maprotiline.	Depression [6A70-6A7Z]	[31]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Morphine and Esketamine.	Depression [6A70-6A7Z]	[33]
Hyoscyamine	DM804UR	Moderate	Additive CNS depression effects by the combination of Morphine and Hyoscyamine.	Digestive system disease [DE2Z]	[40]
Mepenzolate	DM8YU2F	Moderate	Additive CNS depression effects by the combination of Morphine and Mepenzolate.	Digestive system disease [DE2Z]	[35]
5-hydroxy-L-tryptophan	DMDWZGJ	Moderate	Additive serotonergic effects by the combination of Morphine and 5-hydroxy-L-tryptophan.	Discovery agent [N.A.]	[31]
Oxybutynine	DMJPBAX	Moderate	Additive antimotility effects by the combination of Morphine and Oxybutynine.	Discovery agent [N.A.]	[35]
Heroin diacetylmorphine	DMDBWHY	Major	Additive CNS depression effects by the combination of Morphine and Heroin diacetylmorphine.	Dissociative neurological symptom disorder [6B60]	[30]
Trihexyphenidyl	DMB19L8	Moderate	Additive CNS depression effects by the combination of Morphine and Trihexyphenidyl.	Dystonic disorder [8A02]	[41]
Fenfluramine	DM0762O	Moderate	Additive CNS depression effects by the combination of Morphine and Fenfluramine.	Epilepsy/seizure [8A61-8A6Z]	[31]
Diazepam	DM08E9O	Major	Additive CNS depression effects by the combination of Morphine and Diazepam.	Epilepsy/seizure [8A61-8A6Z]	[34]
Primidone	DM0WX6I	Major	Additive CNS depression effects by the combination of Morphine and Primidone.	Epilepsy/seizure [8A61-8A6Z]	[34]
Gabapentin	DM6T924	Major	Additive CNS depression effects by the combination of Morphine and Gabapentin.	Epilepsy/seizure [8A61-8A6Z]	[42]
Clonazepam	DMTO13J	Major	Additive CNS depression effects by the combination of Morphine and Clonazepam.	Epilepsy/seizure [8A61-8A6Z]	[34]
Phenobarbital	DMXZOCG	Major	Additive CNS depression effects by the combination of Morphine and Phenobarbital.	Epilepsy/seizure [8A61-8A6Z]	[34]
Dantrolene	DM1D8XY	Major	Additive CNS depression effects by the combination of Morphine and Dantrolene.	Fever [MG26]	[34]
Solifenacin	DMG592Q	Moderate	Additive antimotility effects by the combination of Morphine and Solifenacin.	Functional bladder disorder [GC50]	[35]
Tolterodine	DMSHPW8	Moderate	Additive CNS depression effects by the combination of Morphine and Tolterodine.	Functional bladder disorder [GC50]	[35]
Darifenacin	DMWXLYZ	Moderate	Additive antimotility effects by the combination of Morphine and Darifenacin.	Functional bladder disorder [GC50]	[35]
Terbinafine	DMI6HUW	Moderate	Decreased metabolism of Morphine caused by Terbinafine mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[43]
Propantheline	DM2EN6G	Moderate	Additive antimotility effects by the combination of Morphine and Propantheline.	Gastric ulcer [DA60]	[35]
Cisapride	DMY7PED	Minor	Altered absorption of Morphine due to GI dynamics variation caused by Cisapride.	Gastro-oesophageal reflux disease [DA22]	[44]
Brimonidine	DMQLT4N	Moderate	Additive CNS depression effects by the combination of Morphine and Brimonidine.	Glaucoma [9C61]	[45]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Morphine caused by Rifampin.	HIV-infected patients with tuberculosis [1B10-1B14]	[46]
Procarbazine	DMIK367	Moderate	Additive CNS depression effects by the combination of Morphine and Procarbazine.	Hodgkin lymphoma [2B30]	[36]
Belladonna	DM2RBWK	Moderate	Additive antimotility effects by the combination of Morphine and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[35]
Suvorexant	DM0E6S3	Major	Additive CNS depression effects by the combination of Morphine and Suvorexant.	Insomnia [7A00-7A0Z]	[34]
Amobarbital	DM0GQ8N	Major	Additive CNS depression effects by the combination of Morphine and Amobarbital.	Insomnia [7A00-7A0Z]	[34]
Ramelteon	DM7IW9J	Major	Additive CNS depression effects by the combination of Morphine and Ramelteon.	Insomnia [7A00-7A0Z]	[34]
Eszopiclone	DM8RZ9H	Major	Additive CNS depression effects by the combination of Morphine and Eszopiclone.	Insomnia [7A00-7A0Z]	[34]
Flurazepam	DMAL4G0	Major	Additive CNS depression effects by the combination of Morphine and Flurazepam.	Insomnia [7A00-7A0Z]	[34]
Triazolam	DMETYK5	Major	Additive CNS depression effects by the combination of Morphine and Triazolam.	Insomnia [7A00-7A0Z]	[34]
Pentobarbital	DMFNH7L	Major	Additive CNS depression effects by the combination of Morphine and Pentobarbital.	Insomnia [7A00-7A0Z]	[34]
Zaleplon	DMGFWSM	Major	Additive CNS depression effects by the combination of Morphine and Zaleplon.	Insomnia [7A00-7A0Z]	[34]
Propiomazine	DMKY8V1	Major	Additive CNS depression effects by the combination of Morphine and Propiomazine.	Insomnia [7A00-7A0Z]	[34]
Tasimelteon	DMLOQ1V	Major	Additive CNS depression effects by the combination of Morphine and Tasimelteon.	Insomnia [7A00-7A0Z]	[34]
Paraldehyde	DMOC1BX	Major	Additive CNS depression effects by the combination of Morphine and Paraldehyde.	Insomnia [7A00-7A0Z]	[34]
ITI-007	DMUQ1DO	Major	Additive CNS depression effects by the combination of Morphine and ITI-007.	Insomnia [7A00-7A0Z]	[34]
Zolpidem	DMWOSKJ	Major	Additive CNS depression effects by the combination of Morphine and Zolpidem.	Insomnia [7A00-7A0Z]	[34]
Quazepam	DMY4D87	Major	Additive CNS depression effects by the combination of Morphine and Quazepam.	Insomnia [7A00-7A0Z]	[34]
Estazolam	DMZGXUM	Major	Additive CNS depression effects by the combination of Morphine and Estazolam.	Insomnia [7A00-7A0Z]	[34]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Morphine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[47]
Clidinium	DMUMQZ0	Moderate	Additive antimotility effects by the combination of Morphine and Clidinium.	Irritable bowel syndrome [DD91]	[35]
Dicyclomine	DMZSDGX	Moderate	Additive antimotility effects by the combination of Morphine and Dicyclomine.	Irritable bowel syndrome [DD91]	[35]
Remimazolam	DMLVSYX	Major	Additive CNS depression effects by the combination of Morphine and Remimazolam.	Labour/delivery anaesthesia complication [JB0C]	[34]
Lumefantrine	DM29GAD	Moderate	Decreased metabolism of Morphine caused by Lumefantrine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[33]
Meprobamate	DMHM93Y	Major	Additive CNS depression effects by the combination of Morphine and Meprobamate.	Malaria [1F40-1F45]	[34]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Morphine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[48]
Zolmitriptan	DM1IB4Q	Moderate	Additive serotonergic effects by the combination of Morphine and Zolmitriptan.	Migraine [8A80]	[31]
Almogran	DM7I64Z	Moderate	Additive CNS depression effects by the combination of Morphine and Almogran.	Migraine [8A80]	[31]
Frovatriptan	DM7RE8P	Moderate	Additive CNS depression effects by the combination of Morphine and Frovatriptan.	Migraine [8A80]	[31]
Rizatriptan	DMDJMA3	Moderate	Additive serotonergic effects by the combination of Morphine and Rizatriptan.	Migraine [8A80]	[31]
Naratriptan	DMO50U2	Moderate	Additive serotonergic effects by the combination of Morphine and Naratriptan.	Migraine [8A80]	[31]
Sumatriptan	DMVYXR8	Moderate	Additive serotonergic effects by the combination of Morphine and Sumatriptan.	Migraine [8A80]	[31]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Morphine and Lasmiditan.	Migraine [8A80]	[49]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Morphine and Flibanserin.	Mood disorder [6A60-6E23]	[50]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Morphine and Thalidomide.	Multiple myeloma [2A83]	[51]
Carisoprodol	DMWR1JC	Major	Additive CNS depression effects by the combination of Morphine and Carisoprodol.	Musculoskeletal disorder [FA00-FC0Z]	[34]
Rifabutin	DM1YBHK	Moderate	Increased metabolism of Morphine caused by Rifabutin.	Mycobacterium infection [1B10-1B21]	[46]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Morphine caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[52]
Prasugrel	DM7MT6E	Moderate	Altered absorption of Morphine due to GI dynamics variation caused by Prasugrel.	Myocardial infarction [BA41-BA43]	[53]
Droperidol	DM0DXA8	Major	Additive cardiorespiratory depression effects by the combination of Morphine and Droperidol.	Nausea/vomiting [MD90]	[54]
Palonosetron	DMBHMOX	Moderate	Additive serotonergic effects by the combination of Morphine and Palonosetron.	Nausea/vomiting [MD90]	[31]
Metoclopramide	DMFA5MY	Moderate	Antagonize the effect of Morphine when combined with Metoclopramide.	Nausea/vomiting [MD90]	[55]
Granisetron	DMIUW25	Moderate	Additive CNS depression effects by the combination of Morphine and Granisetron.	Nausea/vomiting [MD90]	[31]
Dolasetron	DMMG26Z	Moderate	Additive CNS depression effects by the combination of Morphine and Dolasetron.	Nausea/vomiting [MD90]	[31]
Ondansetron	DMOTQ1I	Moderate	Additive serotonergic effects by the combination of Morphine and Ondansetron.	Nausea/vomiting [MD90]	[31]
Bupropion	DM5PCS7	Major	Increased risk of lowers seizure threshold by the combination of Morphine and Bupropion.	Nicotine use disorder [6C4A]	[56]
Sibutramine	DMFJTDI	Moderate	Additive serotonergic effects by the combination of Morphine and Sibutramine.	Obesity [5B80-5B81]	[31]
Dexfenfluramine	DMJ7YDS	Moderate	Additive serotonergic effects by the combination of Morphine and Dexfenfluramine.	Obesity [5B80-5B81]	[31]
Levomethadyl Acetate	DM06HG5	Major	Additive CNS depression effects by the combination of Morphine and Levomethadyl Acetate.	Opioid use disorder [6C43]	[30]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Morphine and Apraclonidine.	Optic nerve disorder [9C40]	[45]
Pentazocine	DM1XBHS	Major	Additive CNS depression effects by the combination of Morphine and Pentazocine.	Pain [MG30-MG3Z]	[57]
Dextropropoxyphene	DM23HCX	Major	Additive CNS depression effects by the combination of Morphine and Dextropropoxyphene.	Pain [MG30-MG3Z]	[58]
Butorphanol	DM5KYPJ	Major	Additive hypotensive effects by the combination of Morphine and Butorphanol.	Pain [MG30-MG3Z]	[57]
Oxymorphone	DM65AGJ	Major	Additive CNS depression effects by the combination of Morphine and Oxymorphone.	Pain [MG30-MG3Z]	[34]
Levorphanol	DMGS80V	Major	Additive CNS depression effects by the combination of Morphine and Levorphanol.	Pain [MG30-MG3Z]	[34]
Hydromorphone	DMHP21E	Major	Additive CNS depression effects by the combination of Morphine and Hydromorphone.	Pain [MG30-MG3Z]	[34]
Dezocine	DMJDB0Y	Major	Additive hypotensive effects by the combination of Morphine and Dezocine.	Pain [MG30-MG3Z]	[57]
Codeine	DMJX6ZG	Major	Additive CNS depression effects by the combination of Morphine and Codeine.	Pain [MG30-MG3Z]	[34]
Flavoxate	DMKV4NL	Moderate	Additive antimotility effects by the combination of Morphine and Flavoxate.	Pain [MG30-MG3Z]	[35]
Nalbuphine	DMOSQGU	Major	Additive CNS depression effects by the combination of Morphine and Nalbuphine.	Pain [MG30-MG3Z]	[57]
Buprenorphine	DMPRI8G	Major	Additive CNS depression effects by the combination of Morphine and Buprenorphine.	Pain [MG30-MG3Z]	[57]
Hydrocodone	DMQ2JO5	Major	Additive CNS depression effects by the combination of Morphine and Hydrocodone.	Pain [MG30-MG3Z]	[34]
Meperidine	DMX4GND	Major	Additive CNS depression effects by the combination of Morphine and Meperidine.	Pain [MG30-MG3Z]	[34]
Oxycodone	DMXLKHV	Major	Additive CNS depression effects by the combination of Morphine and Oxycodone.	Pain [MG30-MG3Z]	[34]
Biperiden	DME78OA	Moderate	Additive CNS depression effects by the combination of Morphine and Biperiden.	Parkinsonism [8A00]	[41]
Procyclidine	DMHFJDT	Moderate	Additive CNS depression effects by the combination of Morphine and Procyclidine.	Parkinsonism [8A00]	[41]
Pimavanserin	DMR7IVC	Major	Additive CNS depression effects by the combination of Morphine and Pimavanserin.	Parkinsonism [8A00]	[34]
Orphenadrine	DMW542E	Major	Additive CNS depression effects by the combination of Morphine and Orphenadrine.	Parkinsonism [8A00]	[34]
Lindane	DMB8CNL	Moderate	Increased risk of lowers seizure threshold by the combination of Morphine and Lindane.	Pediculosis [1G00]	[59]
Methylscopolamine	DM5VWOB	Moderate	Additive CNS depression effects by the combination of Morphine and Methylscopolamine.	Peptic ulcer [DA61]	[35]
Fluphenazine	DMIT8LX	Major	Additive CNS depression effects by the combination of Morphine and Fluphenazine.	Psychotic disorder [6A20-6A25]	[60]
Triflupromazine	DMKFQJP	Major	Additive CNS depression effects by the combination of Morphine and Triflupromazine.	Psychotic disorder [6A20-6A25]	[34]
Celecoxib	DM6LOQU	Moderate	Decreased metabolism of Morphine caused by Celecoxib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[61]
Quetiapine	DM1N62C	Major	Additive CNS depression effects by the combination of Morphine and Quetiapine.	Schizophrenia [6A20]	[60]
Mesoridazine	DM2ZGAN	Major	Additive CNS depression effects by the combination of Morphine and Mesoridazine.	Schizophrenia [6A20]	[60]
Thioridazine	DM35M8J	Major	Additive CNS depression effects by the combination of Morphine and Thioridazine.	Schizophrenia [6A20]	[34]
Aripiprazole	DM3NUMH	Major	Additive CNS depression effects by the combination of Morphine and Aripiprazole.	Schizophrenia [6A20]	[34]
Iloperidone	DM6AUFY	Major	Additive CNS depression effects by the combination of Morphine and Iloperidone.	Schizophrenia [6A20]	[34]
Paliperidone	DM7NPJS	Major	Additive CNS depression effects by the combination of Morphine and Paliperidone.	Schizophrenia [6A20]	[34]
Loxapine	DM8AI9U	Major	Additive CNS depression effects by the combination of Morphine and Loxapine.	Schizophrenia [6A20]	[60]
Haloperidol	DM96SE0	Major	Additive CNS depression effects by the combination of Morphine and Haloperidol.	Schizophrenia [6A20]	[34]
Perphenazine	DMA4MRX	Major	Additive CNS depression effects by the combination of Morphine and Perphenazine.	Schizophrenia [6A20]	[34]
Molindone	DMAH70G	Major	Additive CNS depression effects by the combination of Morphine and Molindone.	Schizophrenia [6A20]	[34]
Chlorpromazine	DMBGZI3	Major	Additive CNS depression effects by the combination of Morphine and Chlorpromazine.	Schizophrenia [6A20]	[60]
Thiothixene	DMDINC4	Major	Additive CNS depression effects by the combination of Morphine and Thiothixene.	Schizophrenia [6A20]	[60]
Clozapine	DMFC71L	Major	Additive CNS depression effects by the combination of Morphine and Clozapine.	Schizophrenia [6A20]	[60]
Trifluoperazine	DMKBYWI	Major	Additive CNS depression effects by the combination of Morphine and Trifluoperazine.	Schizophrenia [6A20]	[34]
Risperidone	DMN6DXL	Major	Additive CNS depression effects by the combination of Morphine and Risperidone.	Schizophrenia [6A20]	[34]
Olanzapine	DMPFN6Y	Major	Additive CNS depression effects by the combination of Morphine and Olanzapine.	Schizophrenia [6A20]	[60]
Asenapine	DMSQZE2	Major	Additive CNS depression effects by the combination of Morphine and Asenapine.	Schizophrenia [6A20]	[34]
Pimozide	DMW83TP	Major	Additive CNS depression effects by the combination of Morphine and Pimozide.	Schizophrenia [6A20]	[34]
Fentanyl	DM8WAHT	Major	Additive CNS depression effects by the combination of Morphine and Fentanyl.	Sensation disturbance [MB40]	[34]
Pitolisant	DM8RFNJ	Moderate	Increased metabolism of Morphine caused by Pitolisant mediated induction of CYP450 enzyme.	Somnolence [MG42]	[32]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Morphine caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[62]
Brilinta	DMBR01X	Moderate	Altered absorption of Morphine due to GI dynamics variation caused by Brilinta.	Thrombosis [DB61-GB90]	[53]
Clopidogrel	DMOL54H	Moderate	Altered absorption of Morphine due to GI dynamics variation caused by Clopidogrel.	Thrombosis [DB61-GB90]	[53]
Tizanidine	DMR2IQ4	Major	Additive CNS depression effects by the combination of Morphine and Tizanidine.	Tonus and reflex abnormality [MB47]	[34]
Atropine	DMEN6X7	Moderate	Additive antimotility effects by the combination of Morphine and Atropine.	Unspecific substance harmful effect [NE6Z]	[35]
Cetirizine	DMOMP9U	Moderate	Additive CNS depression effects by the combination of Morphine and Cetirizine.	Vasomotor/allergic rhinitis [CA08]	[63]
Mexiletine	DMCTE9R	Moderate	Altered absorption of Morphine due to GI dynamics variation caused by Mexiletine.	Ventricular tachyarrhythmia [BC71]	[54]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
Butylated hydroxytoluene	E00336	31404	Antioxidant
D&C red no. 27	E00381	83511	Colorant
D&C red no. 28	E00491	6097185	Colorant
D&C red no. 30	E00456	3000709	Colorant
Diethyl phthalate	E00135	6781	Plasticizing agent; Solvent
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Fumaric acid	E00420	444972	Acidulant; Antioxidant; Complexing agent; Flavoring agent; Solubilizing agent
Hydrazine yellow	E00409	164825	Colorant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Ammonia	E00007	222	Alkalizing agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Butylhydroxyanisole	E00308	24667	Antimicrobial preservative; Antioxidant
Cetostearyl alcohol	E00353	62238	Emollient; Emulsifying agent; Viscosity-controlling agent
Eisenoxyd	E00585	56841934	Colorant
FD&C red no. 3	E00629	Not Available	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Lithol rubin BCA	E00607	135423095	Colorant
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000	E00655	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Potassium hydroxide	E00233	14797	Alkalizing agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium alginate	E00671	Not Available	Binding agent; Disintegrant; Suspending agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water	E00035	962	Solvent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Morphine 15 mg tablet	15 mg	12 HR Extended Release Oral Tablet	Oral
Morphine 200 mg tablet	200 mg	12 HR Extended Release Oral Tablet	Oral
Morphine 60 mg tablet	60 mg	12 HR Extended Release Oral Tablet	Oral
Morphine 130 mg capsule	130 mg	Extended Release Oral Capsule	Oral
Morphine 40 mg capsule	40 mg	Extended Release Oral Capsule	Oral
Morphine 70 mg capsule	70 mg	Extended Release Oral Capsule	Oral
Morphine 30 mg tablet	30 mg	12 HR Extended Release Oral Tablet	Oral
Morphine 80 mg capsule	80 mg	Extended Release Oral Capsule	Oral
Morphine 150 mg capsule	150 mg	Extended Release Oral Capsule	Oral
Morphine 10 mg capsule	10 mg	Extended Release Oral Capsule	Oral
Morphine 100 mg tablet	100 mg	12 HR Extended Release Oral Tablet	Oral
Morphine 30 mg capsule	30 mg	Extended Release Oral Capsule	Oral
Morphine 45 mg capsule	45 mg	24 HR Extended Release Oral Capsule	Oral
Morphine 200 mg tablet	200 mg	Extended Release Oral Tablet	Oral
Morphine 30 mg tablet	30 mg	Extended Release Oral Tablet	Oral
Morphine 90 mg capsule	90 mg	24 HR Extended Release Oral Capsule	Oral
Morphine 100 mg capsule	100 mg	Extended Release Oral Capsule	Oral
Morphine 120 mg capsule	120 mg	24 HR Extended Release Oral Capsule	Oral
Morphine 30 mg capsule	30 mg	24 HR Extended Release Oral Capsule	Oral
Morphine 50 mg capsule	50 mg	Extended Release Oral Capsule	Oral
Morphine 60 mg capsule	60 mg	24 HR Extended Release Oral Capsule	Oral
Morphine 60 mg capsule	60 mg	Extended Release Oral Capsule	Oral
Morphine 200 mg capsule	200 mg	Extended Release Oral Capsule	Oral
Morphine 100 mg tablet	100 mg	Extended Release Oral Tablet	Oral
Morphine 15 mg tablet	15 mg	Extended Release Oral Tablet	Oral
Morphine 75 mg capsule	75 mg	24 HR Extended Release Oral Capsule	Oral
Morphine 20 mg capsule	20 mg	Extended Release Oral Capsule	Oral
Morphine 60 mg tablet	60 mg	Extended Release Oral Tablet	Oral
Morphine 15 mg tablet	15 mg	Oral Tablet	Oral
Morphine 30 mg tablet	30 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Morphine FDA Label
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] BDDCS applied to over 900 drugs
• [4] Paladin Labs - Product Monograph: SANDOMIGRAN (Pizotifen hydrogen malate 0.5 mg and 1 mg tablets)
• [5] Stuart-Harris R, Joel SP, McDonald P, Currow D, Slevin ML: The pharmacokinetics of morphine and morphine glucuronide metabolites after subcutaneous bolus injection and subcutaneous infusion of morphine. Br J Clin Pharmacol. 2000 Mar;49(3):207-14.
• [6] Hoskin PJ, Hanks GW: Morphine: pharmacokinetics and clinical practice. Br J Cancer. 1990 Nov;62(5):705-7.
• [7] Pharmacokinetic-pharmacodynamic modeling of opioids. J Pain Symptom Manage. 2005 May;29(5 Suppl):S90-103. doi: 10.1016/j.jpainsymman.2005.01.012.
• [8] Somani SM, Roberts JB, Wilson A: Pyridostigmine metabolism in man. Clin Pharmacol Ther. 1972 May-Jun;13(3):393-9. doi: 10.1002/cpt1972133393.
• [9] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [10] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [11] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [12] Antianalgesia: stereoselective action of dextro-morphine over levo-morphine on glia in the mouse spinal cord.J Pharmacol Exp Ther.2005 Sep;314(3):1101-8.
• [13] Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch. 2007 Feb;453(5):661-73.
• [14] Genetic variability and clinical efficacy of morphine. Acta Anaesthesiol Scand. 2005 Aug;49(7):902-8.
• [15] Modulation of UDP-glucuronosyltransferase 2B7 function by cytochrome P450s in vitro: differential effects of CYP1A2, CYP2C9 and CYP3A4. Biol Pharm Bull. 2005 Oct;28(10):2026-7.
• [16] Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors. J Pharmacol Exp Ther. 2004 Feb;308(2):547-54.
• [17] Contribution of UDP-glucuronosyltransferase 1A1 and 1A8 to morphine-6-glucuronidation and its kinetic properties. Drug Metab Dispos. 2008 Apr;36(4):688-94.
• [18] In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Dispos. 2005 May;33(5):689-95.
• [19] Molecular cloning of the baboon UDP-glucuronosyltransferase 2B gene family and their activity in conjugating morphine. Drug Metab Dispos. 2010 Apr;38(4):545-53.
• [20] Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab Dispos. 1998 Jun;26(6):507-12.
• [21] Kinetic characterization of cholinesterases and a therapeutically valuable cocaine hydrolase for their catalytic activities against heroin and its metabolite 6-monoacetylmorphine. Chem Biol Interact. 2018 Sep 25;293:107-114.
• [22] Effect of opium addiction on new and traditional cardiovascular risk factors: do duration of addiction and route of administration matter?. Lipids Health Dis. 2008 Nov 3;7:42. doi: 10.1186/1476-511X-7-42.
• [23] Morphine promotes apoptosis in Jurkat cells. J Leukoc Biol. 1999 Oct;66(4):650-8. doi: 10.1002/jlb.66.4.650.
• [24] Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther. 2008 Apr;83(4):559-66.
• [25] Morphine induces apoptosis of human endothelial cells through nitric oxide and reactive oxygen species pathways. Toxicology. 2009 Feb 4;256(1-2):83-91. doi: 10.1016/j.tox.2008.11.015. Epub 2008 Nov 25.
• [26] Morphine induces DNA damage and P53 activation in CD3+ T cells. Biochim Biophys Acta. 2009 Aug;1790(8):793-9. doi: 10.1016/j.bbagen.2009.04.011. Epub 2009 May 3.
• [27] Chronic high-dose morphine treatment promotes SH-SY5Y cell apoptosis via c-Jun N-terminal kinase-mediated activation of mitochondria-dependent pathway. FEBS J. 2009 Apr;276(7):2022-36. doi: 10.1111/j.1742-4658.2009.06938.x.
• [28] Morphine induces Beclin 1- and ATG5-dependent autophagy in human neuroblastoma SH-SY5Y cells and in the rat hippocampus. Autophagy. 2010 Apr;6(3):386-94. doi: 10.4161/auto.6.3.11289. Epub 2010 Apr 25.
• [29] Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J. 2005;5(5):324-36. doi: 10.1038/sj.tpj.6500327.
• [30] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
• [31] Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
• [32] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [33] Cerner Multum, Inc. "Australian Product Information.".
• [34] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
• [35] Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA.
• [36] Evans-Prosser CD "The use of pethidine and morphine in the presence of monoamine oxidase inhibitors." Br J Anaesth 40 (1968): 279-82. [PMID: 5654977]
• [37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
• [38] Gill SS, Wright EM, Reilly CS "Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study." Br J Anaesth 65 (1990): 760-5. [PMID: 2265045]
• [39] Product Information. Avinza (morphine). Ligand Pharmaceuticals, San Diego, CA.
• [40] Product Information. Levorphanol Tartrate (levorphanol). Sentynl Therapeutics, Solana Beach, CA.
• [41] Product Information. Artane (trihexyphenidyl). Lederle Laboratories, Wayne, NJ.
• [42] Eckhardt K, Ammon S, Hofmann U, Riebe A, Gugeler N, Mikus G "Gabapentin enhances the analgesic effect of morphine in healthy volunteers." Anesth Analg 91 (2000): 185-91. [PMID: 10866910]
• [43] AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
• [44] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61. [PMID: 7882635]
• [45] Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
• [46] Fromm MF, Eckhardt K, Li SX, Schanzle G, Hofmann U, Mikus G, Eichelbaum M "Loss of analgesic effect of morphine due to coadministration of rifampin." Pain 72 (1997): 261-7. [PMID: 9272811]
• [47] Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
• [48] Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
• [49] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [50] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [51] Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
• [52] Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
• [53] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
• [54] Canadian Pharmacists Association.
• [55] Product Information. Reglan (metoclopramide). Wyeth-Ayerst Laboratories, Philadelphia, PA.
• [56] Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
• [57] Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
• [58] Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
• [59] Matsuoka LY "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol 5 (1981): 98-9. [PMID: 6168673]
• [60] Cerner Multum, Inc. "Canadian Product Information.".
• [61] Product Information. Celebrex (celecoxib). Searle, Chicago, IL.
• [62] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
• [63] Product Information. Zyrtec (cetirizine). Pfizer US Pharmaceuticals, New York, NY.